血管內(nèi)皮生長(zhǎng)因子B(VEGFB)活性蛋白
Active Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 編號(hào)APA144Hu01
- 物種Homo sapiens (Human，人) 相同的名稱(chēng)，不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)-
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1814 ¥ 4536 ¥ 9072 ¥ 27216 ¥ 68040
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
活性實(shí)驗(yàn)
用法
Reconstitute in 20mM Tris, 150mM NaCl (PH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月，-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA144Hu01 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA144Hu01 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAA144Hu01 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA144Hu71 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAA144Hu81 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| MAA144Hu22 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)單克隆抗體 | WB; IHC; ICC; IP. |
| LAA144Hu82 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)單克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| LAA144Hu72 | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA144Hu | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA144Hu | 血管內(nèi)皮生長(zhǎng)因子B(VEGFB)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379] |
| Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033] |
| Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z] |
| EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [] |
| Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713] |
留言咨詢(xún)
